

APR 23 2002

COPY OF PAPERS  
ORIGINALLY FILEDattala  
paper #9

SHEET 1 OF 1

TECH CENTER 1600/2900

RECEIVED  
APR 25 2002

## FORM PTO - 1449

## INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

FILING DATE: February 9, 2001 GROUP: 1644

## U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
<i>gal</i>	B1	WO 99/43713	9/2/1999	PCT	/	/		No	Yes

## OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
<i>gal</i>	C1	Batova et al., "The Ch14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity <i>in Vitro</i> ," <u>Clinical Cancer Research</u> , <u>5</u> : 4259-4263 (1999).
<i>gal</i>	C2	Gillies et al., "Improving the Efficacy of Antibody-Interleukin 2 Fusion Proteins by Reducing Their Interaction with Fc Receptors," <u>Cancer Research</u> , <u>59</u> : 2159-2166 (1999).
<i>gal</i>	C3	Kendra et al., "Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice," <u>Cancer Immunol Immunother</u> , <u>48</u> : 219-229 (1999).

EXAMINER *David A Saemundson* DATE CONSIDERED *5/28/02*

2302225\_1